新型炎症标志物在肺癌中的应用  

Application of novel inflammatory markers in lung cancer

作　　者：蒋雨珂(综述) 李长毅(审校)[2] JIANG Yuke;LI Changyi(Graduate School,Chongqing Medical University,Chongqing 400010,China;Department of Respiratory Medicine,Second Affiliated Hospital of Chongqing Medical University,Chongqing 400010,China)

机构地区：[1]重庆医科大学研究生院,重庆400010 [2]重庆医科大学附属第二医院呼吸内科,重庆400010

出　　处：《现代医药卫生》2024年第1期111-116,121,共7页Journal of Modern Medicine & Health

基　　金：重庆市自然科学基金项目(cstc2020jcyj-msxm X0472)。

摘　　要：炎症是肿瘤的标志,在肿瘤的发生、发展、转移、预后中发挥重要作用。中性粒细胞、血小板、单核/巨噬细胞、淋巴细胞是肺癌等实体肿瘤微环境的重要组成成分,通过多种机制发挥促炎与抗炎作用。其相关的中性粒细胞与淋巴细胞之比、血小板与淋巴细胞之比、淋巴细胞与单核细胞之比可反映机体炎症状态及促瘤与抗瘤之间的平衡关系,是肺癌筛查、监测病程进展、疗效及预后评估的前景指标。该文就炎症、免疫与肺癌之间的关系,新型炎症标志物在肺癌中的应用进行综述。Inflammation is a hallmark of tumors and plays an important role in tumorigenesis,progression,metastasis and prognosis.Neutrophils,platelets,monocytes/macrophages and lymphocytes are the important components of the solid tumor-associated microenvironment such as lung cancer,and exert pro-and anti-inflammatory effects through multiple mechanisms.Their associated neutrophil-to-lymphocyte ratio,platelet-to-lymphocyteratio and lymphocyte-to-monocyte ratio can reflect the body inflammatory status and the balance between pro-and anti-tumor effects.They are the promising indicators for lung cancer screening,monitoring disease progression,efficacy and prognosis assessment.This paper reviews the relationship among inflammation,immunity and lung cancer,and the application of novel inflammatory markers in lung cancer.

关 键 词：炎症 肺癌 中性粒细胞与淋巴细胞之比 血小板与淋巴细胞之比 淋巴细胞与单核细胞之比 

分 类 号：R734.2[医药卫生—肿瘤]